Updates are available Correction dated 2022-02-18
Click to view Correction: https://doi.org/10.1007/s00428-022-03292-w
-
Authors
Rodriguez Pena, Maria Del Carmen
Springer, Simeon U.
Taheri, Diana
Li, Lu
Tregnago, Aline C.
Eich, Marie-Lisa
Eltoum, Isam-Eldin A.
VandenBussche, Christopher J.
Papadopoulos, Nickolas
Kinzler, Kenneth W.
Vogelstein, Bert
Netto, George J. http://orcid.org/0000-0003-3915-9134
-
Funding
Funding for this research was provided by:
Henry and Marsha Laufer
Virginia and D.K. Ludwig Fund for Cancer Research
National Institutes of Health (T32 GM007309/GM/NIGMS NIH HHS/United States, P30 CA077598/CA/NCI NIH HHS/United States, P30 CA006973/CA/NCI NIH HHS/United States, R01 ES019564/ES/NIEHS NIH HHS/United States)
- License Information
-
More Information
Article History
Received: 7 June 2019
Revised: 8 August 2019
Accepted: 20 August 2019
First Online: 3 September 2019
Change Date: 18 February 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00428-022-03292-w
Compliance with ethical standards
:
: Nickolas Papadopoulos, Ken W Kinzler, and Bert Vogelstein: Founders of Personal Genome Diagnostics and PapGene and advice Sysmex-Inostics. Kinzler and Vogelstein also advise Eisai. Vogelstein is also an advisor to Camden Partners. These companies and others have licensed technologies from Johns Hopkins that are related to the work described in this paper. These licenses are associated with equity or royalty payments to Papadopoulos, Kinzler, Netto, and Vogelstein. Additional patent applications on the work described in this paper may be filed by Johns Hopkins University. The terms of these arrangements are managed by the university in accordance with its conflict of interest policies. The other authors declare that no competing interests exist.
: The Institutional Review Board approved this study.
